Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Boyiadzis, Michael M., Dhodapkar, Madhav V., Brentjens, Renier J., Kochenderfer, James N., Neelapu, Sattva S., Maus, Marcela V., Porter, David L., Maloney, David G., Grupp, Stephan A., Mackall, Crystal L., June, Carl H., Bishop, Michael R.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278156/
https://ncbi.nlm.nih.gov/pubmed/30514386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0460-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars